No Data
No Data
Medicenna Therapeutics up 12% Following Third-Quarter Results
Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones
Medicenna Therapeutics Corp: INTERIM FINANCIAL STATEMENTSREPORT LETTER FROM FOREIGN ISSUER
Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025
Medicenna Reports Updated Data From ABILITY-1 Trial
Updated MDNA11 Monotherapy and Combination Clinical Data From the Ongoing Phase 1/2 ABILITY-1 Study to Be Presented at the 2024 Immunotherapy Bridge Conference